We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)


CTA approval confirms H221 COVIDITY Phase I start

Lighthouse | 30 July 2021


First custom CTC assay development contract

Lighthouse | 29 July 2021

Redx Pharma

RXC004 2mg dose selected for Phase II trials

Lighthouse | 27 July 2021

Redx Pharma

Rezurock approval has positive read across for Redx

Lighthouse | 19 July 2021

Allergy Therapeutics

Strong FY21 trading, but pipeline set to drive future

Update | 14 July 2021


ASCO 2021: Moving towards combinations

Update | 06 July 2021


Hong Kong listing number 13 is a potent symbol

Update | 06 July 2021


So much more than a play on COVID testing

Initiation | 29 June 2021


£20m placing to accelerate Parsortix opportunities

Update | 28 June 2021

Allergy Therapeutics

FY21 pre-close update ahead of market expectations

Lighthouse | 24 June 2021
1 2 3 4 5 6 7 8 9 10 >
311 results found.